Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

rmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate," "believe," "estimate," "expect," "expectation," "should," "would," "project," "plan," "predict," "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past res
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Stanley Global Healthcare Conference -- SHENZHEN, China, Aug. 27 /PRNewswire-Asia-FirstCall/ -- ... ... ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical ... on August 25, 2010 the Compensation Committee of the Company,s ... to purchase a total of 10,000 shares of common stock ... options are intended to be incentive stock options to the ...
Cached Medicine Technology:Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 2Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 3Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 4Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 5Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference 6Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... For the first time, scientists have demonstrated that stem ... of potential to become specialized cell types, which suggests ... of diseases and conditions than scientists originally thought. ... Publishing Group, the research teams of Anthony Atala, M.D., ...
... The Merriman Good Life ... raising awareness of the general public to the value of pets visiting residents of nursing homes ... ... the Daisy Project. The Daisy Project is aimed at raising awareness of the general public ...
... ... DentaSOAK®, a professional dental cleaner powerful enough to kill more than 99% of infection-causing ... ... Oklahoma State University found that mouthguards used regularly are highly contaminated with bacteria and ...
... by many young children in child care settings doubles the ... home-based settings watching significantly more on average than those in ... screen time in child care settings in more than 20 ... child care programs in four states, and was guided by ...
... November 18, 2009 -- When people have malaria, they are ... saliva of a mosquito, infect cells in the liver, and ... the parasites replicate and also begin to expose adhesive proteins ... the cells in the bloodstream. Experiments show that infected ...
... control, expert says , SUNDAY, Nov. 22 (HealthDay News) ... a seemingly endless buffet of food temptation. While some ... deny themselves any holiday treats. , But there are ... Julie Redfern, manager of Nutrition Consult Services at Brigham ...
Cached Medicine News:Health News:New research shows versatility of amniotic fluid stem cells 2Health News:Daisy Project Seeks To Increase Pet Visitation In Nursing Homes 2Health News:DentaSOAK Dental Cleaner Reduces Infection Risk Linked to Mouthguards 2Health News:Daycare may double TV time for young children, study finds 2Health News:Daycare may double TV time for young children, study finds 3Health News:Daycare may double TV time for young children, study finds 4Health News:Measuring and modeling blood flow in malaria 2Health News:Go Healthy, Not Hungry for Holiday Eating 2
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
Medicine Products: